Foresee Pharmaceuticals Co (ROCO:6576) Notes Receivable: NT$0.0 Mil (As of Dec. 2025)


ROCO:6576 Foresee Pharmaceuticals Co Ltd ROCO:6576
58 GF Score
Price NT$83.10
GF Value NT$96.69
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Foresee Pharmaceuticals Co Notes Receivable?

Foresee Pharmaceuticals Co ROCO:6576 58 Notes Receivable is NT$0.0 Mil as of Dec. 2025. GuruFocus rates ROCO:6576 with a GF Score™ of 58/100 and a GF Value™ of NT$96.69 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Foresee Pharmaceuticals Co's Notes Receivable for the quarter that ended in Dec. 2025 was NT$0.0 Mil.

Foresee Pharmaceuticals Co Notes Receivable Related Terms

Foresee Pharmaceuticals Co Notes Receivable Historical Data

* Premium members only.

The historical data trend for Foresee Pharmaceuticals Co's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Foresee Pharmaceuticals Co Notes Receivable Chart

Foresee Pharmaceuticals Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Foresee Pharmaceuticals Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ROCO:6576
58GF Score
Foresee Pharmaceuticals Co Ltd ROCO:6576
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Foresee Pharmaceuticals Co Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of NT$0.0 Mil mean?
Foresee Pharmaceuticals Co (ROCO:6576) has a Notes Receivable of NT$0.0 Mil as of Dec. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Foresee Pharmaceuticals Co and its competitors.
Is Foresee Pharmaceuticals Co's Notes Receivable too high?
Foresee Pharmaceuticals Co's current Notes Receivable is NT$0.0 Mil. Overall, Foresee Pharmaceuticals Co has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Foresee Pharmaceuticals Co's Notes Receivable compare to ZTS and UTHR?
Foresee Pharmaceuticals Co's Notes Receivable of NT$0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Foresee Pharmaceuticals Co and its competitors. Foresee Pharmaceuticals Co's current Notes Receivable is NT$0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Foresee Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Foresee Pharmaceuticals Co (ROCO:6576) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$96.69, compared to a current price of NT$83.10 — trading 14.1% below its estimated fair value. The current Notes Receivable is NT$0.0 Mil. Foresee Pharmaceuticals Co's overall GF Score™ is 58/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Foresee Pharmaceuticals Co (ROCO:6576), the current Notes Receivable is NT$0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Foresee Pharmaceuticals Co (ROCO:6576) Overvalued in 2026?

Based on GuruFocus' analysis, Foresee Pharmaceuticals Co stock appears to be undervalued. The current stock price of NT$83.10 is trading 14.1% below its estimated GF Value™ of NT$96.69. GuruFocus considers Foresee Pharmaceuticals Co to be Modestly Undervalued.

Key valuation signals for ROCO:6576:

  • Notes Receivable: NT$0.0 Mil
  • GF Value™: NT$96.69 vs. price of NT$83.10 (14.1% below fair value)
  • GF Score™: 58/100 with 7 warning signs

No single metric tells the full story. See the ROCO:6576 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Foresee Pharmaceuticals Co Business Description

Address No. 19-3, Sanchong Road, 9th Floor-2, Nangang District, Taipei, TWN, 115
Foresee Pharmaceuticals Co Ltd main activity is applying stabilized injectable formulation (SIF) platform technology to produce products for anticancer and treatment of chronic diseases. Its pipeline includes CAMCEVI (Leuprolide, FP-001), FP-014 (Triptorelin), Aderamastat (FP-025, MMP-12 Inhibitor), Linvemastat (FP-020, MMP-12 Inhibitor), and others. The Group operates business only in a single industry of new drug development, and all of its revenue is generated from Taiwan.
58GF Score

Get the complete analysis for ROCO:6576

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$83.10
Price
NT$96.69
GF Value